{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:50:09Z","timestamp":1794628209111,"version":"4.9.1"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:p> Studies were conducted to evaluate the subchronic and developmental toxicity of Ac-Di-Sol (croscarmellose sodium). In the subchronic study, groups of Sprague-Dawley rats (20\/sex\/group) received 0 (control), 10,000, or 50,000 ppm Ac-Di-Sol in the diet for 90 consecutive days (equivalent to 757 and 893 mg\/kg\/day for males and females fed 10,000 ppm, respectively, and to 3922 and 4721 mg\/kg\/day for males and females fed 50,000 ppm, respectively). No mortality, clinical signs of toxicity, or adverse toxicological effects on hematology or serum chemistry parameters, feed consumption, or ophthalmologic examinations were noted in any treatment group. Body weight gain was depressed in high-dose males during the final 3 weeks. The only treatment-related histological lesion noted was moderate renal mineralization at the corticomedullary junction in one high-dose female. This lesion was not considered a specific effect of Ac-Di-Sol, but rather a secondary effect resulting from a potential increase in urinary p H and renal excretion of sodium due to the high intake of sodium associated with Ac-Di-Sol. In the developmental toxicity study, groups of pregnant Sprague-Dawley rats (25\/group) received 0 (control), 10,000, or 50,000 ppm Ac-Di-Sol in the diet on gestational days 6 to 15. No evidence of maternal, fetal, or embryo toxicity was noted. The no-observed-adverse-effect level (NOAEL) for Ac-Di-Sol in both studies exceeds 50,000 ppm in the diet, which represents doses of 3922 and 4712 mg\/kg\/day, for males and females, respectively. The results of these studies demonstrate the low subchronic oral toxicity and developmental toxicity of Ac-Di-Sol, and support the safe use of Ac-Di-Sol in oral applications such as pharmaceuticals, dietary supplements, and sweetener tablets. <\/jats:p>","DOI":"10.1080\/10915810305108","type":"journal-article","created":{"date-parts":[[2003,9,18]],"date-time":"2003-09-18T22:40:18Z","timestamp":1063924818000},"page":"149-157","source":"Crossref","is-referenced-by-count":9,"title":["Subchronic and Developmental Toxicity Studies in Rats with Ac-Di-Sol Croscarmellose Sodium"],"prefix":"10.1177","volume":"22","author":[{"given":"Christine","family":"Freeman","sequence":"first","affiliation":[{"name":"Aventis Pharmaceuticals, Bridgewater, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra L.","family":"Weiner","sequence":"additional","affiliation":[{"name":"FMC Corporation, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois A.","family":"Kotkoskie","sequence":"additional","affiliation":[{"name":"Novo Nordisk Pharmaceutical, Inc., New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Borzelleca","sequence":"additional","affiliation":[{"name":"Medical College of Virginia, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Butt","sequence":"additional","affiliation":[{"name":"Pathology Associates International, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2003,5,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1016\/0278-6915(95)00068-D"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1016\/0278-6915(95)00069-E"},{"key":"atypb3","unstructured":"European Communities. 1987. Subchronic oral toxicity test, 90-day repeated oral dose using rodent species. In Official Journal of the European Communities, no. L133\/8\u201311, November 18, 1987 (87\/302\/EEC)."},{"key":"atypb4","volume-title":"Ninety-day feeding study in rats with Ac-Di-Sol SD-711 and modified cellulose gum","author":"FMC Corporation","year":"1997"},{"key":"atypb5","volume-title":"Dietary teratology study in rats with Ac-Di-Sol SD-711 and modified cellulose gum","author":"FMC Corporation","year":"1997"},{"key":"atypb6","first-page":"81","volume":"26","author":"Joint FAO\/WHO Expert Committee on Food Additives (JECFA)","year":"1990","journal-title":"WHO Food Additives Series"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4274(98)80634-6"},{"key":"atypb8","unstructured":"Montgomery C. A., and J. L. Seely. 1990. Kidney. In Pathology of the Fischer Rat, ed. G. A. Boorman, S. L. Eurtis, M. R. Elwell, C. A. Montgomery, and W. F. Mackenzie, 134. San Diego, CA: Academic Press."},{"key":"atypb9","volume-title":"OECD principles on good laboratory practice (as revised in 1997)","author":"Organization for Economic Cooperation and Development (OECD)","year":"1998"},{"key":"atypb10","volume-title":"OECD guidelines for the testing of chemicals","author":"Organization for Economic Cooperation and Development (OECD)","year":"1998"},{"key":"atypb11","unstructured":"Scientific Committee for Food, European Commission. 1998. Opinion on use Of cross-linked sodium carboxymethyl cellulose in solid dietary supplements. DG XXXIV SCF Opinion."},{"key":"atypb12","volume-title":"Toxic Substances Control Act (TSCA), Good laboratory practice standards; final rule","author":"U.S. Environmental Protection Agency (U.S. EPA)","year":"1989"},{"key":"atypb13","volume-title":"Toxicological principles for the safety assessment of direct food additives and color additives used in food","author":"U.S. Food and Drug Administration (U.S. FDA) Bureau of Foods","year":"1982"},{"key":"atypb14","volume-title":"Good laboratory practice regulations; final rule","author":"U.S. United States Food and Drug Administration (U.S. FDA)","year":"1987"},{"key":"atypb15","first-page":"243","author":"Weiner, M.","year":"1992","journal-title":"Toxicol Lett"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810305108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810305108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T03:09:47Z","timestamp":1741662587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/10915810305108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1080\/10915810305108"],"URL":"https:\/\/doi.org\/10.1080\/10915810305108","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}